Cefaly Technology announced the launch of 2 new migraine treatment devices: Cefaly Acute and Cefaly Dual.
Cefaly was the first approved external trigeminal nerve stimulation (e-TNS) device for preventing migraine attacks, which is now available for use during an attack with or without aura. The Cefaly Acute device is intended as rescue use during a migraine and the Cefaly Dual combines the Acute treatment with its prophylactic model, the Cefaly 2 (renamed Cefaly Prevent).
The Food and Drug Administration (FDA) approval was based on several studies that demonstrated 1 hour of use with Cefaly Acute could relieve or stop the migraine headache. A double-blind, randomized, placebo-controlled study showed that treatment with Cefaly decreased migraine pain by an average of 65%. Nearly a third of study patients (32%) reported to be pain free within 1 hour.
The Cefaly product line now includes 3 treatments: Cefaly Prevent, Cefaly Acute, and Cefaly Dual. All 3 devices are placed on the forehead through a magnetic connection to a self-adhesive electrode. This then sends micro-impulses through the skin to the upper branches of the trigeminal nerve to relieve headache pain or to prevent an attack. All devices are available to adults by prescription-only.
FDA-approved Cefaly device to stop migraines now available [press release]. Cefaly US; November 29, 2017. Accessed December 14, 2017.
This article originally appeared on MPR